Acelink Therapeutics would like to congratulate our team member Jessica Nario for winning the Bronze or third-place award for The PharmaTimes Clinical Researcher of the Year – The Americas (PTCROY) in 2021. Jessica Nario is Associate Director of Clinical Operations, leading several aspects of clinical study conduct including strategic organization and vendor partnerships, clinical study start-up, execution, and closure for Acelink’s lead molecule AL01211 which is now in clinical development within Australia and USA with a potential expansion in Europe. Jessica is an integral member of the team.
The PharmaTimes Clinical Researcher of the Year – The Americas (PTCROY) competition was designed to recognize and reward the exceptional talent and passion of industry and academic researchers. The PTCROY is both a celebration of professional excellence and development opportunity for nominees. The competition was composed of three unique stages designed to showcase the nominee’s knowledge and expertise in clinical research conduct – spanning from Good Clinical Practice (GCP), ICH, and USA FDA regulatory guidelines or best practices. Among the expertly curated categories, there are Clinical Research Associates, Clinical Research Coordinator, as well as Clinical Trial Manager and Project Manager. After the first challenge of on-line test and the second challenge of assay, the finalists competed in a live on-the-day challenge presenting to a panel of judge who recorded scores across several quantitative and qualitative parameter providing feedback and ranking (Gold, Silver, and Bronze). The virtual awards ceremony was conducted on October 28th 2021.
AceLink Therapeutics would like to applaud Jessica Nario for receiving this prestigious award and thank her for her contributions.
For more information about PharmaTimes Clinical Researcher of the Year – The Americas, visit: https://www.pharmatimes.com/clinical_researcher_americas/overview
About AceLink Therapeutics, Inc.
Founded in 2018, AceLink Therapeutics is an innovative biopharma startup focusing on developing safe and effective medicines to address kidney diseases with high unmet needs. The company’s initial focus is to develop novel therapeutics for genetically associated kidney disorders, such as Fabry disease. For more information, please visit www.acelinktherapeutics.com.
Jerry Shen, Ph.D.
CEO and President
Phone: (925) 262-3145
Email: [email protected]